KR100469936B1 - 사스 바이러스 항원의 세포표면 발현벡터 및 상기 벡터에의해 형질전환된 미생물 - Google Patents

사스 바이러스 항원의 세포표면 발현벡터 및 상기 벡터에의해 형질전환된 미생물

Info

Publication number
KR100469936B1
KR100469936B1 KR10-2004-0040894A KR20040040894A KR100469936B1 KR 100469936 B1 KR100469936 B1 KR 100469936B1 KR 20040040894 A KR20040040894 A KR 20040040894A KR 100469936 B1 KR100469936 B1 KR 100469936B1
Authority
KR
South Korea
Prior art keywords
sars
expression vector
surface expression
cell surface
virus antigen
Prior art date
Application number
KR10-2004-0040894A
Other languages
English (en)
Other versions
KR20040104936A (ko
Inventor
성문희
김철중
정창민
홍승표
이종수
최재철
김광
주니치구로다
부하령
Original Assignee
주식회사 바이오리더스
(주)엠디랩
한국생명공학연구원
(주)바이오리더스재팬
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 바이오리더스, (주)엠디랩, 한국생명공학연구원, (주)바이오리더스재팬 filed Critical 주식회사 바이오리더스
Publication of KR20040104936A publication Critical patent/KR20040104936A/ko
Application granted granted Critical
Publication of KR100469936B1 publication Critical patent/KR100469936B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
KR10-2004-0040894A 2003-06-04 2004-06-04 사스 바이러스 항원의 세포표면 발현벡터 및 상기 벡터에의해 형질전환된 미생물 KR100469936B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020030035993 2003-06-04
KR20030035993 2003-06-04

Publications (2)

Publication Number Publication Date
KR20040104936A KR20040104936A (ko) 2004-12-13
KR100469936B1 true KR100469936B1 (ko) 2005-02-03

Family

ID=36611852

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-0040894A KR100469936B1 (ko) 2003-06-04 2004-06-04 사스 바이러스 항원의 세포표면 발현벡터 및 상기 벡터에의해 형질전환된 미생물

Country Status (10)

Country Link
US (1) US20060140971A1 (ko)
EP (1) EP1629104A4 (ko)
JP (1) JP2006526403A (ko)
KR (1) KR100469936B1 (ko)
CN (1) CN1798844A (ko)
AU (1) AU2004245859B2 (ko)
BR (1) BRPI0411393A (ko)
CA (1) CA2527346A1 (ko)
RU (1) RU2332457C2 (ko)
WO (1) WO2004108937A1 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100872042B1 (ko) 2005-09-14 2008-12-05 주식회사 바이오리더스 마이오스타틴을 발현하는 세포표면 발현벡터 및 상기벡터에 의해 형질전환된 미생물

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050079162A (ko) * 2004-02-04 2005-08-09 주식회사 바이오리더스 파보바이러스 항원의 세포표면 발현벡터 및 상기 벡터에의해 형질전환된 미생물
KR100517114B1 (ko) * 2005-02-25 2005-09-27 주식회사 바이오리더스 폴리감마글루탐산을 함유하는 면역보강제 조성물
US20080206276A1 (en) 2005-07-08 2008-08-28 Michael Otto Targeting Poly-Gamma-Glutamic Acid to Treat Staphylococcus Epidermidis and Related Infections
KR100782332B1 (ko) * 2006-01-23 2007-12-06 주식회사 바이오리더스 새우 흰 반점 바이러스 항원의 표면 발현벡터 및 이에 의해형질전환된 미생물
CN101802169B (zh) * 2007-09-20 2015-11-25 花王株式会社 重组微生物以及聚-γ-谷氨酸的制造方法
JP2014210747A (ja) 2013-04-19 2014-11-13 アンジェスＭｇ株式会社 細胞性免疫誘導能が改善された経口ワクチン
CN107428844A (zh) * 2015-03-05 2017-12-01 发展生物工程与基因技术的彼得和特劳德尔·恩格尔霍恩基金会 用于将肽呈递在细胞表面上的系统
RU2639246C1 (ru) * 2016-12-21 2017-12-20 Федеральное государственное бюджетное учреждение "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов Национального исследовательского центра "Курчатовский институт" (НИЦ "Курчатовский институт" - ГосНИИгенетика) Применение домена белка S-слоя из Lactobacillus brevis в качестве компонента системы для экспонирования слитых белков на поверхности клеток молочнокислых бактерий
WO2020076078A1 (ko) * 2018-10-10 2020-04-16 주식회사 바이오리더스 락토바실러스 카제이 유래 갈락토오스 뮤타로테이즈 유전자의 프로모터를 이용한 항시적 고발현 표면발현벡터 및 그 이용
KR102604524B1 (ko) * 2018-10-10 2023-11-22 주식회사 비엘 락토바실러스 카제이 유래의 두 종류 프로모터를 이용한 두 가지 목적단백질의 동시 표면발현벡터 및 이를 이용한 단백질의 미생물표면 발현 방법
WO2021147025A1 (en) * 2020-01-22 2021-07-29 The University Of Hong Kong-Shenzhen Hospital Anti 2019-ncov vaccine
CN112877351A (zh) * 2020-04-14 2021-06-01 文利新 一种用于防治新冠病毒感染的重组质粒、重组乳酸杆菌表达系统及其应用
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
EP4171574A4 (en) * 2020-06-26 2024-10-23 Elicio Therapeutics Inc COMPOSITIONS AND METHODS FOR INDUSTRIALIZING AN IMMUNE RESPONSE AGAINST CORONAVIRUS
CN112760336A (zh) * 2020-12-30 2021-05-07 广州辉园苑医药科技有限公司 一种抗原表位肽的表达系统和表面展示系统及它们的构建方法
EP4286510A1 (en) * 2021-01-26 2023-12-06 National University Corporation Kobe University Oral coronavirus infection vaccine
KR20220125776A (ko) 2021-03-07 2022-09-14 오영운 돼지갈비 포의 가공 및 분류방법
WO2023022973A2 (en) * 2021-08-16 2023-02-23 Elicio Therapeutics, Inc. Compositions containing polynucleotide amphiphiles and methods of use thereof
WO2023044327A1 (en) * 2021-09-15 2023-03-23 Colorado State University Research Foundation Recombinant vaccine compositions
CN113755421B (zh) * 2021-09-28 2024-04-12 梦芊细胞因子有限公司 一种用于covid-19的口服性疫苗及抗体加强剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001017182A (ja) * 1999-07-09 2001-01-23 Nagase & Co Ltd ポリ−γ−グルタミン酸の製造方法
US7553636B2 (en) * 2001-08-10 2009-06-30 Bioleaders Corporation Surface expression vectors having pgsBCA the gene coding poly-gamma-glutamate synthetase, and a method for expression of target protein at the surface of microorganism using the vector
CN100543140C (zh) * 2002-10-17 2009-09-23 生物领先公司 抗hpv疫苗的载体以及该载体转化的微生物
US20050002953A1 (en) * 2003-05-06 2005-01-06 Jens Herold SARS-coronavirus virus-like particles and methods of use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100872042B1 (ko) 2005-09-14 2008-12-05 주식회사 바이오리더스 마이오스타틴을 발현하는 세포표면 발현벡터 및 상기벡터에 의해 형질전환된 미생물

Also Published As

Publication number Publication date
EP1629104A1 (en) 2006-03-01
BRPI0411393A (pt) 2006-08-01
CA2527346A1 (en) 2004-12-16
KR20040104936A (ko) 2004-12-13
CN1798844A (zh) 2006-07-05
WO2004108937A1 (en) 2004-12-16
AU2004245859A1 (en) 2004-12-16
US20060140971A1 (en) 2006-06-29
RU2332457C2 (ru) 2008-08-27
JP2006526403A (ja) 2006-11-24
EP1629104A4 (en) 2006-11-02
RU2005141528A (ru) 2006-06-27
AU2004245859B2 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
KR100469936B1 (ko) 사스 바이러스 항원의 세포표면 발현벡터 및 상기 벡터에의해 형질전환된 미생물
AU2001243259A1 (en) Genes encoding denitrification enzymes
CY1106334T1 (el) Βελτιστοποιημενου κωδικονιου αλληλουχιες ιου θηλωματος
HK1109421A1 (en) Chimeric adenoviruses for use in cancer treatment
GB0326798D0 (en) Methods for generating mutant virus
NZ597601A (en) Treatment and prevention of influenza
WO2003080807A3 (en) Compositions and methods for suppressing eukaryotic gene expression
WO2006012221A3 (en) Target cell-specific short interfering rna and methods of use thereof
WO2010122367A3 (en) Meganuclease variants cleaving the genomic insertion of a virus and uses thereof
MY156855A (en) Novel regulatory elements
MX2007009628A (es) Virus de acido ribonucleico en replicacion como vacunas.
WO2020127532A3 (en) Rna encoding a protein
AU8491401A (en) Phage-dependent superproduction of biologically active protein and peptides
DK1425404T3 (da) Vaccinia-MVA-E3L-mutanter og anvendelse deraf
WO2008133137A1 (ja) 遺伝子治療のためのベクター
SG156690A1 (en) Mammalian genes involved in infection
UA90098C2 (en) Promoter of vaccinia virus
ATE470708T1 (de) Hyaluronansynthase-gene und expression davon
TNSN07090A1 (en) Novel laccase enzyme and use thereof
EP2434018A3 (en) A novel beta-galactoside-alpha2, 3-sialyltransferase, a gene encoding thereof, and a method for producing thereof
WO2004018630A3 (en) Recombinant double-stranded rna phages and uses thereof
EP1712243A4 (en) GENE THERAPY FOR TUMOR USING A NEGATIVE CHAIN RNA VIRAL VECTOR ENCODING AN IMMUNOSTIMULATORY CYTOKINE
EP1149917A3 (en) Hepatitis B virus vectors for gene therapy
IL174645A0 (en) MODIFIED cDNA FOR HIGH EXPRESSION LEVELS OF FACTOR VIII AND ITS DERIVATIVES
TW200617162A (en) Surface display vector of sars virus antigen and microorganisms transformed thereby

Legal Events

Date Code Title Description
A201 Request for examination
A302 Request for accelerated examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130128

Year of fee payment: 9

FPAY Annual fee payment

Payment date: 20140127

Year of fee payment: 10

LAPS Lapse due to unpaid annual fee